Tau PET Imaging Compounds for Selective Aggregate Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current Tau PET imaging agents face challenges in selectively binding to Tau aggregates while avoiding off-target binding to amyloid-beta and monoamine oxidases, leading to misdiagnosis and limited ability to distinguish between different Tau isoforms and tauopathies, with issues like high unspecific binding and poor pharmacokinetic properties.
Innovation Solution
Development of novel compounds of the formula (II) with high affinity and selectivity for Tau aggregates, capable of binding to both 3R and 4R Tau isoforms, designed to minimize off-target binding and improve brain uptake and washout, reducing background signal interference and defluorination.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current Tau PET imaging agents are used to detect Tau aggregates, then Tau pathology can be visualized, but off-target binding to amyloid-beta and monoamine oxidases occurs leading to misdiagnosis
Solution Approach 1:
The patent applies local quality by designing imaging agents with specific molecular structures that exhibit selective binding properties to Tau aggregates while avoiding off-target binding to amyloid-beta and monoamine oxidases. The chemical structure modifications create localized interaction characteristics that distinguish Tau from other proteins, thereby improving diagnostic reliability by eliminating false positive signals from off-target binding.
Solution Approach 2:
The patent employs parameter changes by optimizing key molecular parameters of the imaging agents including binding affinity constants, selectivity ratios, and pharmacokinetic parameters. By systematically adjusting these parameters through chemical structure variations, the agents achieve high affinity for Tau aggregates while maintaining low affinity for off-target proteins, thus resolving the contradiction between detection capability and off-target binding.
2Adaptability or versatility
If imaging agents bind to both 3R and 4R Tau isoforms, then broader tauopathy detection is achieved, but selectivity among different Tau isoforms becomes difficult
Solution Approach 1:
The patent applies universality by designing imaging agents that can bind to multiple Tau isoforms (both 3R and 4R) with comparable affinity, enabling a single agent to detect various tauopathies including Alzheimer's disease, progressive supranuclear palsy, and corticobasal degeneration. This multi-functional capability allows broad applicability across different Tau pathologies while maintaining sufficient signal differentiation through imaging quantification methods.
3Illumination intensity
If high affinity binding to Tau aggregates is achieved, then signal intensity improves, but background signal interference from non-specific binding increases
Solution Approach 1:
The patent applies the blessing in disguise principle by designing agents where the high affinity binding characteristic that could potentially cause off-target binding is converted into a benefit through selective molecular recognition. The chemical structures are engineered to exploit specific structural features of Tau aggregates (such as beta-sheet conformations and phosphorylated epitopes) while avoiding non-specific interactions, thereby transforming the potential harm of high affinity into the benefit of strong specific signal with minimal background interference.
4Measurement precision
If brain uptake is increased for better imaging, then detection sensitivity improves, but pharmacokinetic properties such as washout rate may be compromised
Solution Approach 1:
The patent applies dynamics by designing imaging agents with optimized pharmacokinetic profiles that exhibit rapid brain uptake followed by efficient washout from non-target regions. The molecular structures are engineered to facilitate quick crossing of the blood-brain barrier for high detection sensitivity, while also enabling rapid clearance through metabolic processes and excretion, thereby achieving both high sensitivity and appropriate kinetic properties for quantitative imaging.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds provide improved selectivity and pharmacokinetic properties, enabling reliable imaging of Tau aggregates in both AD and non-AD tauopathies, reducing misdiagnosis and enhancing diagnostic accuracy through high signal-to-noise ratio and minimal off-target binding.
Implementation Method 1
molecular probes have been used which recognize and bind to the pathological target. Selectivity for binding to pathological Tau protein over other protein depositions in the brain is therefore a basic requirement of a Tau imaging probe.
Data Source
AI summary
The present invention relates to novel compounds of the formula (II)that can be employed in the selective Tau detection of disorders and abnormalities associated with Tau aggregates such as Alzheimer's disease and other tauopathies using Positron Emission Tomography (PET) Imaging.